VIDEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Videx, and when can generic versions of Videx launch?
Videx is a drug marketed by Bristol and Bristol Myers Squibb and is included in four NDAs.
The generic ingredient in VIDEX is didanosine. There are eight drug master file entries for this compound. Additional details are available on the didanosine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VIDEX?
- What are the global sales for VIDEX?
- What is Average Wholesale Price for VIDEX?
Summary for VIDEX
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 123 |
| Patent Applications: | 5,251 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VIDEX |
| What excipients (inactive ingredients) are in VIDEX? | VIDEX excipients list |
| DailyMed Link: | VIDEX at DailyMed |
Paragraph IV (Patent) Challenges for VIDEX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| VIDEX | Capsules | didanosine | 75 mg | 020155 | 1 | 2011-06-06 |
US Patents and Regulatory Information for VIDEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol | VIDEX | didanosine | FOR SOLUTION;ORAL | 020156-001 | Oct 9, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-003 | Oct 9, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX | didanosine | FOR SOLUTION;ORAL | 020155-005 | Oct 9, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-002 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-004 | Oct 9, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX EC | didanosine | CAPSULE, DELAYED REL PELLETS;ORAL | 021183-004 | Oct 31, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers Squibb | VIDEX | didanosine | FOR SOLUTION;ORAL | 020155-003 | Oct 9, 1991 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIDEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-004 | Oct 9, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-005 | Oct 9, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX | didanosine | FOR SOLUTION;ORAL | 020155-003 | Oct 9, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX | didanosine | FOR SOLUTION;ORAL | 020155-006 | Oct 9, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-003 | Oct 9, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX | didanosine | TABLET, CHEWABLE;ORAL | 020154-003 | Oct 9, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Bristol Myers Squibb | VIDEX | didanosine | FOR SOLUTION;ORAL | 020155-005 | Oct 9, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIDEX
See the table below for patents covering VIDEX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 657337 | ⤷ Sign Up | |
| European Patent Office | 0216510 | Inhibition de l'infectivité in vitro et de l'effet cytopathique du HTLV-III/LAV par la 2'3'-didéoxyinosine, la 2'3'-didéoxyguanosine ou par la 2'3'-didéoxyadénosine. (Inhibition of in vitro infectivity and cytopathic effect of HTLV-III/LAV by 2'3'-dideoxyinosine, 2'3'-dideoxyguanosine, or 2'3'-dideoxyadenosine.) | ⤷ Sign Up |
| Russian Federation | 2089193 | PHARMACEUTICAL COMPOSITION FOR ORAL USE BASED ON DEOXYPURINE NUCLEOSIDE AND SHOWING ANTIVIRAL ACTIVITY | ⤷ Sign Up |
| Ireland | 64518 | Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxyinosine 2',3'-dideoxyguanosine or 2',3'-dideoxyadenosine | ⤷ Sign Up |
| South Korea | 960011772 | ⤷ Sign Up | |
| Japan | H04501857 | ⤷ Sign Up | |
| Japan | S62501712 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIDEX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0216510 | SZ 54/1994 | Austria | ⤷ Sign Up | PRODUCT NAME: 2',3'-DIDEOXYINOSIN |
| 0216510 | 94C0006 | Belgium | ⤷ Sign Up | PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505 |
| 0285237 | 94C0006 | France | ⤷ Sign Up | PRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505 |
| 0216510 | SPC/GB94/005 | United Kingdom | ⤷ Sign Up | SPC/GB94/005:, EXPIRES: 20070504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
